[mTOR signal pathway and its inhibitors in antitumor therapy: a review].
Mammalian target of rapamycin (mTOR) is a key downstream molecule of PI3K/Akt pathway. It integrates input signals from growth factors, nutrients and energy to regulate cell growth and proliferation via different cellular processes. Gene mutations of mTOR pathway-related proteins are very common in many carcinomas. Abnormal expression of these related proteins can result in aberrant hyperactivity of mTOR pathway. Therefore, mTOR-targeted therapy has shown promising role in the management of various cancers. This article reviewed the current status of researches on mTOR and its inhibitors in antitumor therapy.
Huang
Jia-Jia
JJ
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, PR China.
Lin
Tong-Yu
TY
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000068338:Everolimus; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011494:Protein Kinases / Q000187:drug effects / Q000378:metabolism*; D015398:Signal Transduction; D020123:Sirolimus / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C515074:ridaforolimus; C401859:temsirolimus; D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus